Germany had opened applications for a fully funded SLE programme at Humboldt University, offering scholarships and training ...

Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics.Pharmace ...

Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...

US FDA accepts Roche’s sBLA for Gazyva/Gazyvaro for the treatment of systemic lupus erythematosus: Basel Wednesday, April 22, 2026, 09:00 Hrs [IST] Roche announced that the US F ...

Ursuline Secondary School trio Ruth O’Connell, Aislinn Smee and Isabel Ralph won the TG4 Slé Anois go Cúramach quiz recently.

Promising early results regarding the use of litifilimab in patients with CLE were presented as part of a late-breaking session at the 2026 AAD Annual Meeting.

Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...

Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus ...

Systemic lupus erythematosus (SLE) involves ongoing inflammation, tissue damage from immune complexes, and incomplete immune resolution. A key factor ...